Targovax ASA: Fourth quarter 2022 results
Oslo, Norway, 16 February 2023 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces its fourth quarter 2022 results. Members of Targovax’s executive management team will give an online presentation to investors, analysts and the press at 10:00 CET today (details below).FOURTH QUARTER 2022 HIGHLIGHTS ONCOS-102 · The phase 1b melanoma study was selected for oral presentation at the prestigious Society for Immunotherapy in Cancer (SITC) annual meeting · The phase 1b melanoma full